MOONITOL ️Mannitol Pharma Grade API is a purified mannitol, C6H14O6, molecular weight 182.17 g/mol, CAS 69-65-8, manufactured for tablet, capsule, granule, oral liquid, and injectable dosage-form production. The product is released against the mannitol monographs of USP-NF, Ph. Eur., JP, and ChP where the site registration applies. It is not a direct-compression excipient blend; it is the active pharmaceutical ingredient and sugar alcohol with compendial identity, purity, and particulate controls. The model variants are segregated by particle-size distribution, residual moisture, and endotoxin control rather than by chemical identity. Release limits include a melting range of 166 °C to 170 °C, specific optical rotation +23.0° to +25.0° on the dried basis, loss on drying not more than 0.5%, sulfated ash not more than 0.1%, chloride not more than 0.014%, sulfate not more than 0.010%, reducing sugars not more than 0.3%, and assay 96.0% to 101.5% on the dried basis. The injection-relevant grade is additionally controlled for bacterial endotoxins by Ph. Eur. 2.6.14 or USP <85>; the acceptance limit is taken from the finished-product monograph or national approval because published data for this specific MOONITOL configuration is limited.

Mannitol differs from lactose and sorbitol in three process-relevant properties. Unlike lactose, mannitol is a non-reducing sugar alcohol and does not carry a reducing aldehyde group in the crystalline state; this reduces the potential for Maillard-type browning with primary amine-containing APIs during wet-granulation or melt processes. Unlike sorbitol, mannitol exhibits low hygroscopicity and remains free-flowing over a wider relative-humidity range. Unlike many co-processed direct-compression sugars, mannitol does not rely on added disaccharide carriers for compaction, although spray-dried grades may contain a controlled amorphous fraction. These distinctions are exploited in amine-sensitive, moisture-sensitive, and sugar-free oral solid dosage forms; compatibility with each formulation must be confirmed under ICH Q1A forced-degradation conditions.

What distinguishes MOONITOL from sorbitol and lactose in direct-compression tablet systems?

In direct compression, mannitol is selected when brittleness under compaction is acceptable and when moisture uptake must be minimised. Lactose monohydrate is a reducing sugar and can undergo Maillard reactions with primary amines; sorbitol is hygroscopic and may plasticise at elevated relative humidity, causing punch sticking and tablet softening. Mannitol compacts predominantly by particle fragmentation and reorganisation, so the resulting tensile strength depends on particle-size distribution, agglomerate porosity, and compaction force. Spray-dried mannitol grades are porous agglomerates that consolidate at lower forces than milled crystalline mannitol; however, excessive force can produce capping and lamination. The direct-compression process window is established on an instrumented rotary tablet press with force and displacement sensors, not inferred from particle-size data alone.

The following compendial release specification matrix condenses the primary chemical and physical controls for the oral and injectable grades. Values are representative monograph requirements; the certificate of analysis for the specific MOONITOL lot is the controlling document.

For granule and capsule operations, particle-size distribution, bulk density, tapped density, and flow function are more decisive than chemical purity alone. Particle-size distribution is determined by laser diffraction ISO 13320-1:2020 or analytical sieving Ph. Eur. 2.9.38; bulk and tapped density are obtained by USP <616> Method I; powder flow is evaluated by angle of repose or flow through an orifice according to USP <1174>. Free-flowing mannitol for high-speed capsule filling generally requires an angle of repose below 35° and a compressibility index below 20%, but these are process targets rather than compendial release limits. Fine-grained mannitol can be improved by addition of 0.5% to 1.0% w/w colloidal silicon dioxide or by spray-dried agglomeration; the optimum glidant level is established by Design of Experiments because excessive glidant can reduce tablet hardness and slow dissolution.

Wet granulation with mannitol requires a deliberate binder strategy because mannitol is freely soluble in water. In high-shear mixer granulation, addition of an aqueous binder above critical liquid saturation can dissolve mannitol crystal surfaces, and subsequent drying can produce hard, fused granules with reduced compressibility. Ethanol-water mixtures or low-water-activity binders are therefore used when granulation end-point and particle-size distribution must be kept narrow. Drying should be controlled by loss-on-drying monitoring at intervals; the mannitol melting point is high enough to permit conventional fluid-bed drying, but the inlet air temperature and product moisture should be validated for each site. Granule flow and bulk density after drying are typically more important than residual solvent alone because mannitol is anhydrous and does not form a monohydrate.

For capsule filling machines using dosator or tamping-pin technology, mannitol powder performance is governed by powder bed compressibility and mass flow under vibration. A low density and high fine fraction can cause weight variation due to inconsistent dosator plug formation. Spray-dried agglomerates or roller-compacted granules are therefore preferred over fine milled powder. Capsule fill weight, weight variation, and dissolution are tested under USP <711> and the product monograph. The mannitol API itself does not require a separate dissolution specification; release is based on identity, purity, and physical properties.

Injection-grade endotoxin control and osmotic function

For injectable dosage forms, mannitol is used to adjust tonicity or to provide a crystalline bulking matrix in freeze-dried products. The final osmolality is measured by freezing-point depression according to USP <785> or Ph. Eur. 2.2.35; a 20% w/v mannitol solution has a theoretical osmolarity near 1098 mOsmol/L, with measured values dependent on temperature and dissolution level. Injection-grade mannitol must meet the bacterial endotoxin limit of the target finished-product monograph. Bacterial endotoxin testing is performed by the limulus amebocyte lysate method of Ph. Eur. 2.6.14 or USP <85>; method suitability for the mannitol matrix must be demonstrated on each instrument platform. The dry API is not necessarily sterile; if a sterile mannitol powder is required, the supplier must provide a grade released for sterility by Ph. Eur. 2.6.1 or USP <71>, or the finished product must be sterilised by an appropriate terminal or aseptic process.

For injectable solutions, the dissolved API should be filtered through a validated membrane and sterilised in final packaging. Mannitol solutions are susceptible to crystal formation if stored below solubility limits; the solubility of mannitol in water is limited compared with sorbitol, and a 20% w/v solution is near the solubility limit at room temperature and may crystallise on cooling. This operational boundary is relevant for manufacturing of hyperosmolar infusion concentrates.

Mannitol can crystallise in α, β, and δ polymorphs; the β form is the thermodynamically stable ambient modification. Spray-dried and lyophilised mannitol may contain metastable δ mannitol or amorphous fractions. This introduces a physical stability boundary: amorphous mannitol can recrystallise on storage at elevated humidity, altering specific surface area, moisture sorption, tablet hardness, and reconstitution time. The polymorphic profile is assessed by powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC); the β-mannitol melt endotherm is observed near 166 °C to 170 °C. In lyophilised injectable cakes, mannitol crystallisation during freezing is controlled by annealing above the glass transition of the maximally freeze-concentrated amorphous phase, a parameter determined by differential scanning calorimetry for the finished formulation. Lot-to-lot variability in amorphous content can affect collapse temperature and cake appearance; therefore, incoming material should be characterised for polymorphic content when the dosage form is freeze-dried.

When residual reducing sugars exceed pharmacopoeial limits in fermentation-derived mannitol

Mannitol obtained by fermentation may contain sorbitol, iditol, or reducing sugar impurities. The compendial reducing-sugars limit of 0.3% is not simply a purity marker; it is a stability threshold for formulations containing primary amine APIs. Above this value, the likelihood of chemical incompatibility increases under open storage at 40 °C/75% RH and during wet massing. Pharmacopoeial methods use a copper tartrate reduction procedure and express the result as glucose; this value is not automatically equivalent to total aldehydic impurities measured by HPLC with pulsed amperometric detection. For amine-sensitive formulations, a lot-specific compatibility study is required; compliance with the reducing-sugar limit alone does not establish chemical stability. Process chromatographic data for residual sorbitol should be requested when mannitol is used in parenteral formulations, because sorbitol can affect osmolality and may be subject to separate monograph limits.

In dry granulation, mannitol is compacted on a roller compactor with controlled roll speed, roll gap, and hydraulic pressure. Because mannitol is brittle, it may produce a high fraction of fines after milling. This can be addressed by optimising the screen size and rotor speed; however, published data for this specific MOONITOL configuration is limited. The granule porosity and particle-size distribution should be monitored because they govern downstream tablet strength.

On production-scale rotary tablet presses, mannitol direct-compression blends are sensitive to the interaction of pre-compression force, main compression force, and turret speed. Because compaction is dominated by brittle fragmentation, excessive dwell time or over-compression can generate elastic recovery layers that lead to capping; low compaction force can produce low tensile strength and friability failures. The process window is established using instrumented tooling with strain-gauge or piezoelectric force sensors, and many mannitol direct-compression formulations are evaluated between 80 MPa and 200 MPa compaction pressure. This range is equipment-specific and must be adjusted for tooling geometry, punch tip diameter, and formulation composition. Ejection force should be monitored because mannitol does not self-lubricate well; magnesium stearate levels above 1.0% w/w may prolong disintegration and reduce tensile strength, especially when blending is extended. Tablet hardness, friability, disintegration, and dissolution are controlled by USP <1217>, USP <1216>, USP <701>, and the finished dosage form monograph.

The API should be stored in well-closed containers below 25 °C and protected from moisture. Because mannitol has low hygroscopicity, environmental exposure below 60% RH during weighing and dispensing rarely requires pre-drying; however, direct-compression and injectable grades should be protected from cyclic humidity because surface moisture can alter flow and electrostatic behaviour. Mannitol is incompatible with strong oxidising agents under acidic or heating conditions; no specific instability with common machine surfaces is documented, but stainless steel contact parts are standard. Residual solvents are controlled per Ph. Eur. 5.4 or USP <467> when production solvents are used. Elemental impurities are risk-assessed under ICH Q3D; suppliers should provide documentation for Class 1, 2A, and 2B elements, with particular attention to palladium or nickel if catalytic hydrogenation is used in mannitol manufacture.